• 中文核心期刊要目总览
  • 中国科技核心期刊
  • 中国科学引文数据库(CSCD)
  • 中国科技论文与引文数据库(CSTPCD)
  • 中国学术期刊文摘数据库(CSAD)
  • 中国学术期刊(网络版)(CNKI)
  • 中文科技期刊数据库
  • 万方数据知识服务平台
  • 中国超星期刊域出版平台
  • 国家科技学术期刊开放平台
  • 荷兰文摘与引文数据库(SCOPUS)
  • 日本科学技术振兴机构数据库(JST)
Gangadhara R Sareddy, Ratna K. Vadlamudi. Cancer therapy using natural ligands that target estrogen receptor beta[J]. 中国天然药物, 2015, 13(11): 801-807.
引用本文: Gangadhara R Sareddy, Ratna K. Vadlamudi. Cancer therapy using natural ligands that target estrogen receptor beta[J]. 中国天然药物, 2015, 13(11): 801-807.
Gangadhara R Sareddy, Ratna K. Vadlamudi. Cancer therapy using natural ligands that target estrogen receptor beta[J]. Chinese Journal of Natural Medicines, 2015, 13(11): 801-807.
Citation: Gangadhara R Sareddy, Ratna K. Vadlamudi. Cancer therapy using natural ligands that target estrogen receptor beta[J]. Chinese Journal of Natural Medicines, 2015, 13(11): 801-807.

Cancer therapy using natural ligands that target estrogen receptor beta

Cancer therapy using natural ligands that target estrogen receptor beta

  • 摘要: Estrogen receptor beta (ER) is one of the two key receptors (ER, ER) that facilitate biological actions of 17-estradiol (E2). ER is widely expressed in many tissues, and its expression is reduced or lost during progression of many tumors. ER facilitates estrogen signaling by both genomic (classical and non-classical) and extra-nuclear signaling. Emerging evidence suggests that ER functions as a tissue-specific tumor suppressor with anti-proliferative actions. Recent studies have identified a number of naturally available selective ER agonists. Targeting ER using its naturally available ligands is an attractive approach for treating and preventing cancers. This review presents the beneficial actions of ER signaling and clinical utility of several natural ER ligands as potential cancer therapy.

     

    Abstract: Estrogen receptor beta (ER) is one of the two key receptors (ER, ER) that facilitate biological actions of 17-estradiol (E2). ER is widely expressed in many tissues, and its expression is reduced or lost during progression of many tumors. ER facilitates estrogen signaling by both genomic (classical and non-classical) and extra-nuclear signaling. Emerging evidence suggests that ER functions as a tissue-specific tumor suppressor with anti-proliferative actions. Recent studies have identified a number of naturally available selective ER agonists. Targeting ER using its naturally available ligands is an attractive approach for treating and preventing cancers. This review presents the beneficial actions of ER signaling and clinical utility of several natural ER ligands as potential cancer therapy.

     

/

返回文章
返回